Atrial cardiopathy and cognitive impairment

Myers, Sarah J.; Jiménez‐Ruiz, Amado; Sposato, Luciano A.; Whitehead, Shawn N.

doi:10.3389/fnagi.2022.914360

Cited by 4 publications

(3 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low cardiac output of HF patients is one of the key reasons for cerebral hypoperfusion, which is critical to cognitive function. Another cause of CCH is the impairment of vascular autoregulation after HF ( 34 , 35 ). Disruption of vascular autoregulation impairs vasodilation function, making it difficult to maintain sufficient CBF in a state of low cardiac output.…”

Section: Risk Factors Of Cardiogenic Dementiamentioning

confidence: 99%

Heart–brain interaction in cardiogenic dementia: pathophysiology and therapeutic potential

Liu,

Xiao,

Liang

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Diagnosis and treatment of patients with cardiovascular and neurologic diseases primarily focus on the heart and brain, respectively. An increasing number of preclinical and clinical studies have confirmed a causal relationship between heart and brain diseases. Cardiogenic dementia is a cognitive impairment caused by heart dysfunction and has received increasing research attention. The prevention and treatment of cardiogenic dementia are essential to improve the quality of life, particularly in the elderly and aging population. This study describes the changes in cognitive function associated with coronary artery disease, myocardial infarction, heart failure, atrial fibrillation and heart valve disease. An updated understanding of the two known pathogenic mechanisms of cardiogenic dementia is presented and discussed. One is a cascade of events caused by cerebral hypoperfusion due to long-term reduction of cardiac output after heart disease, and the other is cognitive impairment regardless of the changes in cerebral blood flow after cardiac injury. Furthermore, potential medications for the prevention and treatment of cardiogenic dementia are reviewed, with particular attention to multicomponent herbal medicines.

show abstract

Section: Risk Factors Of Cardiogenic Dementiamentioning

confidence: 99%

Heart–brain interaction in cardiogenic dementia: pathophysiology and therapeutic potential

Liu,

Xiao,

Liang

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Potentially, this property might help with screening for early signs of cognitive dysfunction [ 44 ]. Several markers indicative of atrial cardiomyopathy, a structural and functional disorder of the left atrium, such as increased brain natriuretic peptide and left atrial enlargement, were also associated with an increased risk for cognitive impairment [ 45 ].…”

Section: Cognitive Decline and Dementia In Common Cardiac Disordersmentioning

confidence: 99%

Chronic Neuroinflammation and Cognitive Decline in Patients with Cardiac Disease: Evidence, Relevance, and Therapeutic Implications

Traub

Frey

Störk

2023

Life

View full text Add to dashboard Cite

Acute and chronic cardiac disorders predispose to alterations in cognitive performance, ranging from mild cognitive impairment to overt dementia. Although this association is well-established, the factors inducing and accelerating cognitive decline beyond ageing and the intricate causal pathways and multilateral interdependencies involved remain poorly understood. Dysregulated and persistent inflammatory processes have been implicated as potentially causal mediators of the adverse consequences on brain function in patients with cardiac disease. Recent advances in positron emission tomography disclosed an enhanced level of neuroinflammation of cortical and subcortical brain regions as an important correlate of altered cognition in these patients. In preclinical and clinical investigations, the thereby involved domains and cell types of the brain are gradually better characterized. Microglia, resident myeloid cells of the central nervous system, appear to be of particular importance, as they are extremely sensitive to even subtle pathological alterations affecting their complex interplay with neighboring astrocytes, oligodendrocytes, infiltrating myeloid cells, and lymphocytes. Here, we review the current evidence linking cognitive impairment and chronic neuroinflammation in patients with various selected cardiac disorders including the aspect of chronic neuroinflammation as a potentially druggable target.

show abstract

“…Consequently, continuous anticoagulant medication is required in all three atrial fibrillation entities if CHA 2 DS 2 -VASc Score ≥ 2 [ 68 ]. Previous studies have revealed that atrial cardiomyopathy, even in the absence of atrial fibrillation, is a risk factor for stroke and cognitive impairment [ 71 , 72 , 73 ]. The detection rate of new-onset atrial fibrillation after cryptogenic stroke ranged between 5% and 25%, depending on the heart-rhythm monitoring method [ 74 , 75 , 76 , 77 ].…”

Section: Biomarkers Of Atrial Cardiomyopathy: Serological Electrophys...mentioning

confidence: 99%

Atrial Cardiomyopathy in Valvular Heart Disease: From Molecular Biology to Clinical Perspectives

Molnár

Sánta

Pásztor

et al. 2023

Cells

View full text Add to dashboard Cite

This review discusses the evolving topic of atrial cardiomyopathy concerning valvular heart disease. The pathogenesis of atrial cardiomyopathy involves multiple factors, such as valvular disease leading to atrial structural and functional remodeling due to pressure and volume overload. Atrial enlargement and dysfunction can trigger atrial tachyarrhythmia. The complex interaction between valvular disease and atrial cardiomyopathy creates a vicious cycle of aggravating atrial enlargement, dysfunction, and valvular disease severity. Furthermore, atrial remodeling and arrhythmia can predispose to atrial thrombus formation and stroke. The underlying pathomechanism of atrial myopathy involves molecular, cellular, and subcellular alterations resulting in chronic inflammation, atrial fibrosis, and electrophysiological changes. Atrial dysfunction has emerged as an essential determinant of outcomes in valvular disease and heart failure. Despite its predictive value, the detection of atrial fibrosis and dysfunction is challenging and is not included in the clinical routine. Transthoracic echocardiography and cardiac magnetic resonance imaging are the main diagnostic tools for atrial cardiomyopathy. Recently published data have revealed that both left atrial volumes and functional parameters are independent predictors of cardiovascular events in valvular disease. The integration of atrial function assessment in clinical practice might help in early cardiovascular risk estimation, promoting early therapeutic intervention in valvular disease.

show abstract

Atrial cardiopathy and cognitive impairment

Cited by 4 publications

References 73 publications

Heart–brain interaction in cardiogenic dementia: pathophysiology and therapeutic potential

Heart–brain interaction in cardiogenic dementia: pathophysiology and therapeutic potential

Chronic Neuroinflammation and Cognitive Decline in Patients with Cardiac Disease: Evidence, Relevance, and Therapeutic Implications

Atrial Cardiomyopathy in Valvular Heart Disease: From Molecular Biology to Clinical Perspectives

Contact Info

Product

Resources

About